Douglas “Doug” Langa was appointed Senior Vice President, Head of
North America Operations and President of Novo Nordisk Inc. in March
2017 and was promoted to Executive Vice President, North America
Operations and President of Novo Nordisk Inc. in August 2017. In this
role, Mr. Langa has full business responsibility for Novo Nordisk’s
largest sales region, comprised of the United States and Canada.
Prior to his current role, Mr. Langa served as Senior Vice
President, Market Access, where he was responsible for securing
formulary access with key payer customers for Novo Nordisk brands. The
Market Access function at Novo Nordisk covers payer marketing,
contract strategy, pricing, and account management for all promoted
and in-line brands. Under Mr. Langa’s leadership, the Market Access
account executive team has received numerous third-party recognitions
for their performance allowing a broad number of patients with chronic
diseases to benefit from having access to Novo Nordisk brands.
Mr. Langa previously served as Corporate Vice President, Market
Access. He joined Novo Nordisk in 2011 as the Senior Director, Managed
Markets, in which he was responsible for strategy development and
execution across Novo Nordisk’s diabetes portfolio.
Mr. Langa joined Novo Nordisk from GlaxoSmithKline (GSK), where
he was the Senior Director of Payer Marketing. Prior to GSK, he
spent the majority of his career at Johnson and Johnson, where he
held various roles of increasing responsibility within Managed
Markets, Sales Leadership, and Marketing. He has over 25 years of
experience in the pharmaceutical and medical device industry.
Mr. Langa graduated from Widener University, earned his MBA
from Fordham University, and holds professional certificates from
The Wharton School and Harvard Business School.